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INTHODUCTION 
That 6-mercaptopurine has an inhibitory effect 
on certain malignant cells is well documented. In 
microorganisms and mammalian cells, this purine ana-
logue is oxidized to 6-thiouric acid by the enzyme 
responsible for metabolism of purine bases, xanthine 
oxidase. Certain compounds which inhibit xanthine 
oxidase potentiate the antitumor effect of 6-rnercapto-
purine noted above. 
Six-mercaptopurine has also been shown to pro-
duce malformations in fetal rats when injected during 
the proper stage of embryonic development. Demonstra-
tion that 4-hydroxypyrazolo-(3,4-d)-pyrimidine, a 
potent xanthine oxidase inhibitor, is non-teratogenic 
but capable of potentiating the teratogenic effect 
of 6-mercaptopurine would draw an interesting parallel 
between the action of 6-mercaptopurine against rapidly 
growing, relatively undifferentiated cells, out of 
control, as in malignancy, and under control, as in 
the developing fetus. The purpose of this investi-
gation was to demonstrate in this manner that such a 
parallel does exist, in order to clarify the mode of 
teratogenic action of 6-mercaptopurine. 
1 • 
HISTOtilCAL HEVIEH 
Experimental Teratology 
General Considerations 
Congenital malformations have in recent years 
been recognized as one of the leading causes of infant 
mortality and morbidity. In earlier times the con-
genitally deformed were considered monstrosities, evil, 
objects of the "wrath of God 11 or "acts of the devil". 
¥any were non-viable and chiefly of interest to anato-
mists and pathologists. However, modern medicine has 
effected such changes in the patterns of human mor-
bidity and mortality tnat ten times as many children 
now die as a result of congenital malformations as of 
five contagious diseases once greatly feared ll). 
This relative increase in the incidence of congenital 
malformations has placed added emphasis on clinical 
and experimental investigation in the field. 
Whenever a medical problem exists, reproduction 
of the pathologic phenomena in animal experiments is 
of value. In the past, however, experimental produc-
tion of congenital malformations has generally failed 
to satisfy those interested in the etiology of anoma-
lies in children, although these investigations have 
been performed in lower animals for nearly a century. 
Complaints have commonly been that mammals have a 
2. 
co~pletely different maternal-fetal relationship, or 
that agents used to produce anomalies are unphysiolog1c 
and without parallel in the human. The latter criti-
cism was applied to the first teratologic metnod prac-
ticed in mammals during the first decade of this cen-
tury: the administration of x-rays to the pregnant 
mother! Not until about two decades ago when it 
became possible to produce malformations experimentally 
in mammals by maternal dietary deficiencies were these 
arguments to some degree overcome. 
Classification of Etiologic Factor~ 
The field of experimental mammalian teratology 
is generally acknowledged to date from Hale's work 
reported in 1~33 (2); piglets from a sow raised on 
a vitamin A-deficient diet were born without eyes. 
Since that time literature in the field has grown 
quite extensive. Only a brief classification of 
factors known to cause experimental congenital mal-
formations will be presented here; excellent review 
articles have been prepared by Kalter and Warkany (lJ, 
~arkany and Kalter (3J, Hillemann t4J, and ~ilson (SJ. 
I. Genetic factors (3,4) 
A. Gene mutations 
B. Chromosome abnormalities 
1. Chromosome excess 
3. 
II. 
2. Chromosome deficiency 
3. Translocation of genes 
4. Transduction of genes 
5. Deletion of genes 
6. Crossing-over of genes 
c. Embryonic instability, or inheritance of 
susceptibility to congenital 
deformity ( 6) 
Nutritional factors { 1, 4) 
A. Vitamin deficiency or antagonism 
1. Vitamin A ( 2 ) 
2. Thiamine 
3. Riboflavin ( 7 ) 
4. Niacin ( 0) 
5. Pantothenic acid {~) 
6. Cobalamin (!U) 
7. Folic acid ( 11-14) 
8 
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Vitamin c 
9. Vitamin J) {15) 
1 i.). Vitamin E ( 16) 
B. Vitamin excess 
1. Vitamin A {17) 
c. Amino acid antagonism 
1. Leucine (18) 
D. Fasting (6,l~J 
4. 
E. Nucleic acid antagonism (20-23) 
F. Galactose \24) 
III. Hormonal factors (1,4) 
A. Pituitary preparations 
1. Anterior pituitary extract 
a. Growth hormone 
b. ACTH 
2. Posterior pituitary extract 
B. Estrogen 
c. Insulin deficiency and excess 
D. Thyroid deficiency and excess 
E. Corticosteroid hormones (2~,26) 
IV. Mechanical and physical factors 
A. Amniocentesis (27) 
B. Direct physical trauma or mechanical 
injury (4) 
c. Hyper- and hypothermia (28) 
D. Anoxia {2:::;) 
V. Antibiotics (4) 
A. 3treptomycin 
B. Tetracycline 
c. Penicillin 
VI. Inorganic materials (4j 
A. Carbon monoxide 
B. Carbon dioxide 
5. 
c. Thallium and lead nitrates 
D. Boric acid 
E. 11 Heavy water 11 tD 2o) 
VIL. Organic materials and drugs 
A. Trypan Blue dye {3UJ 
B. Nicotine t31) 
c. 5-Hydroxytryptamine {32, 33) 
D. Colchicine (34) 
E. Nitrogen mustard (35,22) 
F. Triethylenemelamine (TEM) l36) 
G. Triethylenephosphoramide {TEPAJ {36) 
H. Various other drugs, factors and 
ch emi ca 1 s ( 1 , 4 ) 
VIII. Radiation (37,3dJ 
Significance of Teratologic Investigation 
From the preceding representative but incomplete 
outline, it can be seen that a large variety of 
methods are now available for the experimental pro-
duction of congenital malformations. The types of 
anomalies produced and structures affected are 
equally as variable. In addition, malformations are 
but one manifestation of reproductive failure, and 
these methods are usually also capable of causing 
other disturbances such as sterility, abortion, fetal 
resorption, or neonatal death. It is in fact 
6. 
relatively easy to interrupt pregnancy by environ-
mental interference; it is more difficult to obtain 
viable offspring with congenital malformations, since 
this requires an experimental arrangement that permits 
damaging the embryo without killing it. To achieve 
such balance, the timing, the type of teratogenic 
agent, and its dosage must all be coordinated. 
These varied investigations have demonstrated 
that each embryologic process has its critical period; 
damage done by a teratogenic procedure depends largely 
upon which structures are undergoing critical develop-
ment at the time the procedure is applied. Similarly, 
damage to those structures cannot be produced after 
the critical period of development has passed. On the 
other hand, the investigations have clearly shown that 
teratogens also have their specificities. Acute 
agents attack the embryo once and demonstrate that 
specific malformations are produced at particular 
embryologic stages, while other agents are chronic, 
staying with the mother throughout pregnancy and 
acting only when the embryo is sensitive to them. In 
addition, agent specificity of different teratogens 
cannot be denied. While one agent may produce a 
given anomaly with great effectiveness, another may 
not, even though the agents are applied at the same 
7. 
gestational stage. 
The action of chronic teratogens is comparable 
in some respects to that of genes; these hereditary 
factors are also present throughout the organogenetic 
period but appear to act only at certain stages of 
development. All teratogens (both acute and chronic) 
have other points of resemblance to genes. For instance, 
some induced malformations simulate hereditary defects, 
that is, are 11 phenocopies 11 • Just as genes often have 
11 pleiotropic 11 effects, so teratogens may produce 
variable syndromes, or cause malformations in a variety 
of organs that seem unrelated to each other in post-
natal life. From"these points it may be reasonable to 
deduce that environmental factors sometimes produce 
phenocopies by altering developmental processes in 
the same way gene changes or mutations do. Since little 
is known about the biochemical reactions of genes that 
lead to malformations, a knowledge of the reactions 
that lead to their phenocopies may be of value in 
elucidating the mode of action of faulty genes. For 
example, vitamins act as prosthetic groups in enzymes 
engaged in vital metabolic activities; if enzymes par-
ticipate in biochemical reactions that determine 
channels of embryonic development, then absence of a 
vitamin may result in the interruption of a biochemical 
8. 
sequence, much as the action of a biochemical mutant 
does, which eventually leads to abnormal channels of 
development (1). 
These methods for producing specific malforma-
tions have thus proved of great value as models whereby 
general mechanisms leading to congenital malformations 
in mammals, especially humans, can be studied. 
6-Mercaptopurine 
General Considerations 
The synthesis of 6-mercaptopurine (6-MPJ was 
first described by Elion and Hitchings {3Y) in 1Y52. 
It had originally been studied during the systematic 
investigation of substituted purines for antagonists 
of nucleic acid synthesis (40). Attention was focused 
on the drug when early reports of its inhibitory 
effects on microorganisms {41), experimental tumors 
{42), and mouse leukemias {43) appeared, and in 1Y53 
temporary remissions in certain cases of acute human 
leukemia following 6-MP therapy were reported (44). 
Since that time, clinical use of this purine analogue 
has been well documented and its biologic and bio-
chemical effects extensively studied (45). 
The teratogenic action of 6-MP in mammals was 
first reported by Thiersch in 1~54 {46). Following 
a single oral ingestion of the drug at varying times 
9. 
in their pregnancy, female rats gave birth to large 
numbers of stunted or stillborn fetuses. No gross 
malformations were noted in the survivors, but doses 
administered were small. Fetuses were most sensitive 
to the effects of the drug on the seventh and eighth 
day of gestation. 
In 1Y56 Didcock and coworkers attempted to inter-
rupt pregnancy in rabbits with intra-amniotic injec-
tions of 6-MF {47). The increased number of abortions 
noted was accompanied by the unexpected presence of 
fetuses with congenital malformations; the fetuses 
were viable at term. 
A detailed study of the teratogenic effects of 
antitumor compounds was published by Murphy in 1Y60 (20). 
She reported observing fetal skeletal malformations 
following single intraperitoneal injections of 6-VP 
into pregnant rats on the twelfth day of gestation. 
Sross anomalies were carefully recorded and consisted 
of stunting, pointed noses, shortened extremities, 
fused digits, and rudimentary rear legs and tail. This 
paper provided the technical basis for the present 
investigation. 
Metabolism 
Six-mercaptopurine closely follows the known 
pathways for anabolism and catabolism of purine bases. 
10. 
The analogue is a competitive inhibitor of xanthine 
oxidation (48) and is oxidized to 6-thiouric acid by 
microorganisms and mammalian cells (4~, 50). 
Desulfurization occurs in mice, as indicated by 
sulfate-s35 excretion and labeling of nucleic acid 
d • d • f ,. Mp ;.., " 14 l' 45) l ' 1 d a enine an guanine rom 0-,,1 -v-1,, ; a.oe e 
hypoxanthine and purine nucleotides have also been 
recovered in microorganisms following labeled 6-MP 
administration (49). In addition to 6-thiouric acid, 
6-methylmercaptopurine has been identified as an 
excretion product of 6-MP metabolism (51), and a 
considerable amount of the drug is excreted in the 
urine unchanged or bound as a glucuronide (52,53). 
Conversion of 6-MP to its ribotide has been reported 
(54-56), indicating that the analogue undergoes at 
least the initial steps toward incorporation into 
nucleic acids. This enzymatic conversion is illus-
trated in Chart 1, while Chart 2 summarizes the known 
and postulated pathways of 6-LlP metabolism (57). 
SH 
N~N~ :-OCQH6 Mg+: ~):) +pp; 
N N 0-®·® ~".Jl I ®-OCHQO 
H OH OH 
OH OH 
Chart 1. ~nzymatic synthesis of b-mercaptopurine ribo-
nucleotide by reaction of the base with 5-phospho-
ribosyl-1-pyrophosphate. 
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Anabolism 
MP ribonucleoside 
phosphorylase ~ "''---.. ..........._lkinaseJ 
~yrophosphorylase ~ 
6-Mercaptopurine M~ ribonucleotide 
Catabolism 
--- \ 
----- ~ inosinic ~ polyphosphates 
acid polynucleotides 
xanthine 
oxidase 
xanthine 
oxidase 
6-~ercaptopurine 6-thio- > 6-thiouric 
acid L xanthine 6-methylmercaptopurine 
sulfate; hypoxanthine; anabolic and cata-
bolic products of purine metabolism 
Chart 2. The metabolism of 6-mercaptopurine in vivo 
Mechanism of Action 
Prior to 1Y4d it was assumed that nucleic acid 
purines were entirely synthesized de nova from formate, 
glycine, carbon dioxide, and ammonium salts. At that 
time a report appeared which indicated that preformed 
purines can be interconverted and incorporated into 
nucleic acids {5d); it was eventually supported by 
further investigation t5~,6UJ. The exact mechanism 
of action of 6-MP is unknown, but the best theory is 
based on the above premise. 
Six-mercaptopurine and other analogues of adenine 
and guanine are believed to interfere with incorporation 
12. 
of preformed purines to form nucleic acids and 
purine-containing coenzymes (2u). Bacterial data 
indicate that the primary site of action is at the 
interconversion, through a hypoxanthine derivative, 
of guanine and adenine ribonucleotides. Formation 
of the ribonucleotides is competitively inhibited by 
6-iJ'P ( 61 j. The apparent inl11bi tion of de ~ 
purine synthesis by 6-~P may be related to interference 
with the conversion of inosinic acid to appropriate 
adenine and guanine derivatives, although there is 
evidence that, in leukemic blood cells, enzyme inhibi-
tion by 6-MP occurs prior to the formation of inosinic 
acid (62). Another alternative is that blocking of 
~~purine synthesis by 6-f11~F is a manifestation of 
what is now termed feedback inhibition or end-product 
inhibition (57). A number of investigators have 
recognized that unlabeled purines prevent or depress 
the incorporation into the purine structure of labeled 
precursors. 
Ellis and LeFage (63) have shown that cells 
susceptible to 6-thioguanine incorporate significant 
amounts of the purine antimetabolite into their nucleic 
acids, while resistant cells incorporate only minor 
amounts. The possibility still remains that in addi-
tion to competitively inhibiting normal nucleic acid 
13. 
synthesis in the manner described above, 6-MP may 
actually be incorporated in toto in place of adenine 
or guanine into the nucleic acid molecule, as is 
thioguanine. 
No studies have been performed to determine the 
mechanism of action of 6-MP against developing fetal 
cells; it has been assumed that the drug acts in a 
similar manner against normal and malignant cells. 
The present investigation was designed to test that 
assumption. 
4-Hydroxypyrazolo-(3,4-d)-pyrimidine 
In an attempt to correlate details of chemical 
structure with activity, a systematic investigation 
of purines and their analogues has been under way 
for a number of years (64,65). In the process, syn-
thesis of the pyrazolo-(3,4-d)-pyrimidine ring system 
was undertaken to provide new compounds isomeric with 
various biologically active purines. The pyrazolo-
(3,4-d)-pyrimidines differ from the purines by virtue 
of a pyrazole rather than imidazole ring attached to 
the pyrimidine moiety (66). At least one of these 
compounds, 4-aminopyrazolo-(3,4-d)-pyrimidine, an 
adenine isomer, has demonstrated significant antitumor 
activity (67). 
At the same time in parallel studies, a substantial 
14. 
number of these compounds were found to be inhibitors 
of xanthine oxidase-catalyzed reactions {6d). Since 
this enzyme catalyzes the oxidation of 6-MP to 6-thio-
uric acid (SU), Elion and coworkers decided to deter-
mine whether 6-MP oxidation could be inhibited in yivo, 
and whether the apparent potency and possibly the 
chemotherapeutic index of 6-MP could be altered by 
this means (52). Four-hydroxypyrazolo-(3,4-d)-pyri-
midine (HPP) was the compound chosen for trial; it 
had high potency as a xanthine oxidase inhibitor, only 
moderate toxicity, and no antitumor activity against 
the test systems (67). Chart 3 provides a comparison 
of the structures of 6-MP and HPP. 
6SH 
0-......s 7 
IN C-N 
I II ~H 8 
2C C-N/ ~N/4 9 
3 H 
6-MF 
40H 
....... c, 9 3 
5 N.-- C-C~ 
I II N 2 
6 C:-... C-N/ 
"- N....-8 H 
7 I 
HPP 
Chart 3. Comparison of the structures of 6-MP and HPP. 
Experiments performed on tumor cells in both the 
mouse and human demonstrated that inhibition of xanthine 
oxidase activity is attained in vivo when HPP is 
administered, and that such inhibition results in a 
decrease in the metabolic destruction of 6-MP (52). 
15. 
MATEN:IALS AND METHODS 
Pregnant albino rats (Sprague-Dawley strain) were 
obtained from the Holtzman Xat Company, Madison, Wis-
consin. The day the animals were sperm positive was 
called gestation day zero. They were housed no more 
than four to a cage in air conditioned quarters and 
given Kockland rat chow and tap water ad libitum. 
On gestation day 12, all animals were injected 
intraperitoneally with a l.J ml suspension of 6-MP 1 
and/or HPP2 in the approximate dosages listed on the 
following page in Table I. Amounts of each drug 
injected were one fifth the values listed, as all rats 
weighed approximately 200 grams, and prior experiments 
had demonstrated that more precise dosages were not 
necessary to assure uniform production of anomalies. 
The drugs were suspended in carboxymethylcellulose 
due to their insolubility at a physiologic pH. use 
of this inert gum as a vehicle assured more uniform 
dosages; its viscosity minimized error caused by 
settling out of the drugs. 
On gestation day 20, 1-2 days before parturition, 
the rats were sacrificed by cervical dislocation and 
the fetuses delivered by Caesarean section, a procedure 
1. Nutritional Biochemicals Corporation, Cleveland, Ohio. 
2. Aldrich Chemical Company, Mil·waukee, '.Visconsin. 
16. 
Table I 
Dosaae Schedule 
Total N c>". 
Dosage No. Paternal Fetuses 
Drug Injected (mg/kg) Hats Injected Examined 
Control-No Injection 
Contra 1-CMC-l:-
( Ca rboxymethyl cellulose) 
6-Percaptopurine ( 6-'.\P) 
4-Hydroxypyrazolo-
( 3, 4-d )-pyrimidine (HFF) 
6-i.~t-' plus 
I-lFF 
HFP 
6-!''l-- plus 
HFP 
Totals 
12 
13 
60 15 
120 5 
6U 
120 5 
15 y 
30 lu 
15 
3U y 
7'd 
* All drugs were injected in CMC, lU mg/ml. 
125 
114 
127 
48 
57 
83 
101 
SJ6 
7 51 
necessary as experimental young allowed to deliver nor-
mally were eaten by the mother. The fetuses were 
examined closely for evidence of malformations or still-
birth, and the uteri, for resorption sites. Placentas 
were separated from the fetuses, and the latter were 
blotted dry, weighed on a Mettler semi-micro balance, 
and quick-frozen for subsequent study. NO further 
processing was done prior to x-ray examination. 
Fetuses to be stained were transferred to Y5){, 
17. 
ethanol for at least 72 hours to assure adequate 
fixation. They were then carefully skinned and placed 
in several changes of l~ potassium hydroxide for 
clearing. This step required 4-7 days; unless the 
soft tissues were entirely transl~cent, they would 
take up stain. 
After clearing 1 the fetuses were placed in U.Ul~ 
Alizarin ~ed 3 stain in l~ potassium hydroxide until 
the desired depth of staining was noted {approximately 
6-12 hours). Clearing was completed in several 
changes of 2U parts glycerin: 80 parts l~ potassium 
hydroxide. The fetuses were then transferred through 
a graded glycerin series and stored in pure glycerin 
{6~). 
18. 
riE..:lJLT::l 
Figure 1 illustrates the gross appearance after 
ethanol fixation of a control fetus and one whose 
mother r-eceived a teratogenic dose of 6-l~'<P \60 mg/kg). 
Though viable at the ti~e of Caesarean section, the 
latter fetus demonstrates stunting of growth, genera-
lized throughout the body but propor-tionally more 
severe at the caudal end. Gross shortening of the 
tail is noted, together with retardation or absence 
of digital development, or syndactyly. The digital 
anomaly is more pronounced on the hind legs; at least 
two toes commonly appear on the forefeet, whereas 
complete fusion or lack of differentiation of adja-
cent phalanges and metatarsals is the rule on the 
hind feet. 
The presence of an umbilical hernia can be seen; 
although appearing inconsistently, this malformation 
was present in over half the fetuses examined, and the 
abdominal wall defect was in some instances quite 
extensive. Other inconsistently appearing defects 
a re 11 s c r a mb 1 e d 11 s t er nab r a e l 71.J ) and an as a r ca • In 
many fetuses sternal ossification centers could not 
be seen, but wnen present they were often deformed and 
irregular. Anasarca was noted only in those fetuses 
most severely affected. 
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X-rays were taken at different milliamperage, 
time, and kilovoltage settings and on several types 
of film to obtain best possible skeletal detail. 
The films were printed directly (Figure 2) or photo-
graphed and the resulting negative printed (Figure 3). 
Neither negative nor positive print adequately demon-
strates fetal structJre due to lack of bone density 
at this stage of development, but stunting of growth 
and abnormalities of the ribs and spine can be seen. 
Differential staining proved to be the better 
method for visualization of bony structure. Com-
parison of the stained skeletons of control and 
experimental fetuses reveals in the latter retardation 
or absence of ossification of metacarpal, metatarsal, 
and phalangeal centers (Figures 4,~,7) and absence of 
one of the two lower leg bones (Figure 7). Both radius 
and ulna, however, were invariably present (Figure 5). 
'P.arked branching and fusing of the ribs can be seen 
(Figure 5), and a degree of spina bifida is suggested 
by divergence and irregularity of the lateral pro-
cesses of the lumbar and sacral vertebrae, with dupli-
cation of the central vertebral body (Figure 6). 
Of note was the consistency of the above findings. 
Although malformations varied to a small extent in 
severity (probably due to differences in absolute drug 
20. 
dosage between litters and to variations in fetal 
susceptibility within the litter), no unaffected 
fetuses were obtained from maternal animals receiving 
6-MP at the teratogenic dosage. At the other extreme, 
no increase in intrauterine death was apparent, as 
judged by the lack of increase in numner of still-
births or uterine resorption sites. 
One-fourth the teratogenic dosage of 6-~F (15 
mg/kg) caused no apparent change in fetal development; 
no malformations could be found (Figure 8), and fetal 
weight was not significantly different from control 
values 1 • The same results were obtained after the 
injection of HPP at 30 and 120 mg/kg. However, when 
6-~P (15 mg/kg) and H~P (30 mg/kg) were given together, 
~alformations identical to those obtained with the 
teratogenic dose of 6-I5P (60 mg/kg) alone were noted 
(Figures ~,Y). The combination of the teratogenic 
dose with HPP (120 mg/kg) resulted not in malformations 
but in rapid fetal death. 
1. Unpublished data. 
21. 
D ISCiJSS ION 
Four-hydroxypyrazolo-(3,4-d)-pyri~idine has 
previously been reported to potentiate the antitumor 
action of 6-mercaptopurine. The data above indicate 
that this xanthine oxidase inhibitor has a similar 
ability to potentiate the teratogenic action of 6-MP. 
This finding suggests the possibility that 6-MP acts 
at a similar site in malignant and fetal cells and 
establishes a precedent for consideration of the 
mechanism of action in both instances as identical. 
That anomalies produced following 6-YP adminis-
tration are due to 6-LlP rather than one of its meta-
bolites (53) has not yet been proven, but this investi-
gation indicates the excretory end product, 6-thiouric 
acid, and the intermediary metabolite of xanthine oxi-
dation, 6-thioxanthine (57), are not the responsible 
agents. If they were, addition of HPP would prevent 
or lessen the anomalies obtained, since 6-thiouric 
acid and 6-thioxanthine would not be formed enzymati-
cally from 6-MP. On the other hand, if 6-MP or one 
of its metabolites from pathways other tnan that 
involving xanthine oxidase were the teratogenic agent, 
addition of HFF would increase the severity of the 
anomalies or increase the effectiveness of 6-MP at a 
lower dosage. Both were the case. When HPP was added 
22. 
to the teratogenic aose of 6-~P, fetal death occurred 
shortly after administration, as demonstrated by small 
fetal size and extensive resorption. 6econdly, fetal 
anomalies obtained with one-fourth the teratogenic 
dose of 6-MP in combination with HPP resembled those 
obtained with the teratogenic dose of 6-MP alone. 
On the basis of these findings, further studies 
are being carried out to determine the exact nature 
of 6-MP teratogenesis. It is hoped that this investi-
gation may eventually shed light on the broader pro-
blem of drug-induced teratogenesis in the human. In 
addition, since a parallel has been established between 
action of 6-~P against fetal and malignant cells, 
results obtained from study of 6-MP-induced congenital 
anomalies may find secondary application to problems 
in the field of cancer chemotherapy and finally, help 
to elucidate the larger problem of the nature of 
malignant growth in general. 
23. 
SUMl~ARY AND CONCLUSIONS 
Congenital malformations are produced in fetal 
rats by a single intraperitoneal injection of the 
purine analogue 6-mercaptopurine into pregnant rats 
at the critical stage of gestation. Photographs and 
descriptions of these malformations are presented. 
Administration of 4-hydroxypyrazolo-lJ,4-dJ-
pyr1mi6ine (a xanthine oxidase inhibitor) with non-
teratogenic doses of 6-mercaptopurine results in 
similar congenital malformations. Combination of the 
former drug with teratogenic doses of the latter 
causes fetal death. It has thus been demonstrated 
that 4-hydroxypyrazolo-(3,4-d)-pyrimidine potent1ates 
the teratogenic action of 6-mercaptopurine, as well 
as its antitumor activity, which has been previously 
reported. 
24. 
Figure 1. Gross appearance after ethanol fixation 
of a control and experimental fetus at twenty days 
of gestation. Stunting of growth, shortening of 
the tail, retardation or absence of development of 
hind legs and feet, and umbilical hernia can be 
clearly seen. 
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Figure 2. Direct print taken from an x-ray of a 
control and experimental fetus. The x-ray film was 
exposed at 30Umilliamperes, 3U kilovolts for one 
second. Although indistinct, stunting of growth 
and abnormalities of the ribs and spine can be 
seen. 
26. 

Figure 3. Indirect print of fetuses in Figure 2. 
The x-ray film was photographed and the resulting 
negative printed. Original x•ray exposure was 3UU 
milliamperes, 30 kilovolts, for 2.5 seconds. 
27. 
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Figure 4. Differential staining of a control and 
experimental fetus. This method provides much 
better visualization of skeletal detail. Back-
lighting was produced by photographing the fetuses 
on an x-ray view box. 
-- --: 
CONTROL 6-MP 
60 MG/KG 
Figure 5. Close-up view of the experimental 
fetus pictured in Figure 4. Note the marked 
branching and fusing of ribs. Both radius and 
ulna can be identified on the right, but one of 
the two lower leg bones (probably the fibula) is 
characteristically absent bilaterally. 
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Figure 6., Close-up view of the spines of exper1-
mental { 6-f·!}, 6U mg/kg) and control fetus es. The 
experimental fetus has been bisected transversely 
to allow viewing of the spine in one plane. 
Lateral processes of the lumbar and sacral verte-
brae are irregular and can be seen to diver~e; 
together with duplication of the vertebral centra, 
this suggests a degiee of spina bifida. 
• 
Figure 7. Hind legs from control and experimental 
{6-IAP, 6U mg/kg) fetuses. rtetarded or absent 
development of ossification centers, stunting of 
growth, and absence of one lower leg bone (probably 
the fibula) are all visible. 
31. 
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Figure a. Effect of HPP. It is evident that 
while 6-MP (15 mg/kg) and HPP (3U and 12U mg/kg) 
had no effect on the fetus, the administration of 
HPP (30 mg/kg) in combination with 6-MP (15 mg/kg) 
resulted in anomalies identical in type to those 
caused by 6-MP (6U mg/kg), but to somewhat less 
severe a degree. 
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,, "' 
HPP 6-MP 6-MP 15 MG/KG+ 
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Figure Y. Fetus whose mother received 6-UF llS 
mg/kg) and H~P (30 mg/kg) compared with a control 
fetus. All skeletal anomalies previously described 
with 6-rliP (60 mg/kg) can be identified in this. 
fetus, such as divergence and irregularity of the 
lateral processes of the lumbar and sacral verte-
brae with double vertebral centra, marked branching 
and f~sing of the ribs, absence of one of the two 
lower leg bones, and lack of digital aevelopment, 
with retardation or absence of ossification of 
metacarpal, metatarsal, and phalangeal centers. 
'· 
.. 
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